Tobramycin Patent Expiration
Tobramycin is Used for treating cystic fibrosis patients infected with Pseudomonas aeruginosa. It was first introduced by Novartis Pharmaceuticals Corp
Tobramycin Patents
Given below is the list of patents protecting Tobramycin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tobi Podhaler | US10207066 | Aerosolization apparatus with capsule puncture alignment guide | Nov 04, 2030 | Viatris |
| Tobi Podhaler | US8869794 | Aerosolization apparatus with capsule puncturing member | Sep 12, 2028 | Viatris |
| Tobi Podhaler | US7559325 | Aerosolization apparatus with air inlet shield | Oct 27, 2025 | Viatris |
| Tobi Podhaler | US8664187 | Methods of treatment of endobronchial infections |
Jun 20, 2025
(Expired) | Viatris |
| Tobi Podhaler | US11484671 | Aerosolization apparatus with capsule puncture alignment guide |
Nov 07, 2024
(Expired) | Viatris |
| Tobi Podhaler | US8069851 | Aeorosolization apparatus with air inlet shield |
Sep 24, 2024
(Expired) | Viatris |
| Tobi Podhaler | USRE47526 | Aerosolization apparatus with air inlet shield |
Apr 09, 2024
(Expired) | Viatris |
| Tobi Podhaler | US7516741 | Aerosolization apparatus with feedback mechanism |
Jan 11, 2024
(Expired) | Viatris |
| Bethkis | US7696178 | Optimised formulation of tobramycin for aerosolization |
Mar 17, 2023
(Expired) | Chiesi |
| Tobi Podhaler | US7368102 | Pulmonary delivery of aminoglycosides |
Dec 19, 2022
(Expired) | Viatris |
| Tobi Podhaler | US8715623 | Pulmonary delivery of aminoglycoside |
Dec 19, 2022
(Expired) | Viatris |
| Tobi Podhaler | US9421166 | Pulmonary delivery of aminoglycoside |
Dec 19, 2022
(Expired) | Viatris |
| Bethkis | US6987094 | Optimized formulation of tobramycin for aerosolization |
Sep 22, 2022
(Expired) | Chiesi |
| Bethkis | US7939502 | Optimised formulation of tobramycin for aerosolization |
Jun 14, 2022
(Expired) | Chiesi |
| Tobi Podhaler | US7097827 | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
Jun 27, 2021
(Expired) | Viatris |
| Tobi Podhaler | US7442388 | Phospholipid-based powders for drug delivery |
May 10, 2020
(Expired) | Viatris |
| Tobi Podhaler | US8349294 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
May 10, 2020
(Expired) | Viatris |
| Tobi | US5508269 | Aminoglycoside formulation for aerosolization |
Oct 19, 2014
(Expired) | Viatris |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Tobramycin's patents.
Latest Legal Activities on Tobramycin's Patents
Given below is the list recent legal activities going on the following patents of Tobramycin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Court Processing Terminated | 17 Apr, 2024 | US7516741 |
| Maintenance Fee Reminder Mailed Critical
| 15 Apr, 2024 | US9421166 |
| Court Processing Terminated | 01 Mar, 2024 | US7097827 |
| Court Processing Terminated | 28 Feb, 2024 | US7442388 |
| Recordation of Patent Grant Mailed Critical
| 01 Nov, 2022 | US11484671 |
| Patent Issue Date Used in PTA Calculation Critical
| 01 Nov, 2022 | US11484671 |
| Email Notification Critical
| 13 Oct, 2022 | US11484671 |
| Issue Notification Mailed Critical
| 12 Oct, 2022 | US11484671 |
| Application Is Considered Ready for Issue Critical
| 26 Sep, 2022 | US11484671 |
| Dispatch to FDC | 26 Sep, 2022 | US11484671 |
Tobramycin's Family Patents
